Holen Sie sich die Stockscreener-App
1.02
3.77%
-0.04
Schlusskurs vom Vortag:
$1.06
Offen:
$1.09
24-Stunden-Volumen:
1.08M
Relative Volume:
1.41
Marktkapitalisierung:
$55.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.56M
KGV:
-0.8718
EPS:
-1.17
Netto-Cashflow:
$-35.28M
1W Leistung:
+19.84%
1M Leistung:
+4.65%
6M Leistung:
-39.29%
1J Leistung:
-52.34%
1-Tages-Spanne:
$1.015
$1.13
1-Wochen-Bereich:
$0.8342
$1.13
52-Wochen-Spanne:
$0.703
$2.20
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corporation
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Vergleichen Sie PDSB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.02 | 58.00M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corporation Aktie (PDSB) Neueste Nachrichten
Stocks of PDS Biotechnology Corporation (PDSB) are poised to climb above their peers - Setenews
PDS Biotechnology Secures New Patent for PDS0101 - TipRanks
PDS Biotech secures new patent for cancer immunotherapy in Japan - Investing.com
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan - The Manila Times
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why - sharewise.com
How supply chain issues affect PDS Biotechnology Corporation stock2025 Macro Impact & AI Powered Market Trend Analysis - Newser
A better buy-in window may exist right now for PDS Biotechnology Corporation (PDSB) - Setenews
Is PDS Biotechnology Corporation stock ready for breakoutOptions Play & Real-Time Volume Spike Alerts - Newser
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration - marketscreener.com
PDS Biotech secures FDA meeting to discuss accelerated approval pathway By Investing.com - Investing.com Nigeria
PDS Biotech secures FDA meeting to discuss accelerated approval pathway - Investing.com
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ('FDA”) - The Manila Times
PDS Biotech announces scheduling of Type C meeting with U.S. Food and Drug Administration - marketscreener.com
PDS Biotech (Nasdaq: PDSB) Plans FDA Talk on PFS Endpoint in VERSATILE-003 Trial - Stock Titan
Energy Moves: How interest rate cuts could boost PDS Biotechnology Corporation stock2025 Volatility Report & Capital Efficiency Focused Ideas - BỘ NỘI VỤ
Adversity is less terrifying than hope: PDS Biotechnology Corporation (PDSB) - Setenews
B. Riley Cuts PDS Biotechnology (NASDAQ:PDSB) Price Target to $3.00 - Defense World
History Review: How interest rate cuts could boost PDS Biotechnology Corporation stockPortfolio Growth Summary & Precise Buy Zone Tips - BỘ NỘI VỤ
PDS Biotechnology price target lowered to $3 from $5 at B. Riley - Yahoo Finance
B. Riley Securities Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq
B. Riley Adjusts Price Target on PDS Biotechnology to $3 From $5, Maintains Buy Rating - marketscreener.com
Can PDS Biotechnology Corporation stock reach $100 price targetMarket Performance Report & Growth Focused Investment Plans - newser.com
PDS Biotechnology Shares Face Market Pressure Despite Clinical Promise - Ad-hoc-news.de
What dividend safety score for PDS Biotechnology Corporation stock2025 Market Overview & Real-Time Volume Analysis Alerts - newser.com
Why PDS Biotechnology Corporation stock is recommended by analysts2025 Top Decliners & Growth Focused Stock Reports - newser.com
Earnings visualization tools for PDS Biotechnology CorporationOil Prices & Verified Technical Signals - newser.com
PDS Biotechnology Corporation’s volatility index tracking explainedInflation Watch & Breakout Confirmation Alerts - newser.com
Advanced analytics toolkit walkthrough for PDS Biotechnology CorporationCPI Data & Daily Oversold Bounce Ideas - newser.com
Is PDS Biotechnology Corporation stock a good choice for value investorsInflation Watch & Safe Entry Point Identification - newser.com
It makes sense and dollars to buy PDS Biotechnology Corporation (PDSB) stock - Setenews
Is PDS Biotechnology Corporation stock entering bullish territoryJuly 2025 Highlights & Consistent Growth Equity Picks - newser.com
PDS Biotechnology Corp (EU6.DU) stock price, news, quote and history - Yahoo Finance Singapore
Tools to assess PDS Biotechnology Corporation’s risk profilePortfolio Performance Report & Consistent Return Investment Signals - newser.com
Multi factor analysis applied to PDS Biotechnology CorporationWeekly Volume Report & Weekly Chart Analysis and Guides - newser.com
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2025 Earnings Call Transcript - Insider Monkey
Will PDS Biotechnology Corporation stock go up soonWeekly Investment Recap & AI Based Buy and Sell Signals - newser.com
Will PDS Biotechnology Corporation stock reach all time highs in 2025Earnings Growth Summary & Long-Term Safe Return Strategies - newser.com
PDS Biotechnology: Q3 Earnings Snapshot - New Haven Register
PDS Biotechnology Trims Losses And Aims For Accelerated Drug Approval - Finimize
PDS Biotechnology: Promising Trial Results and Financial Update - TipRanks
Earnings call transcript: PDS Biotech beats EPS expectations in Q3 2025 - Investing.com UK
HC Wainwright & Co. Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq
PDS Biotechnology Corp (PDSB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Q3 2025 Earnings Report - MarketBeat
Earnings call transcript: PDS Biotech beats EPS expectations in Q3 2025 By Investing.com - Investing.com South Africa
Finanzdaten der Pds Biotechnology Corporation-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):